TRANSCRIPTOMICS - Realising the promise with a new era of drug discovery and diagnostics By Dr Bruce Seligmann The advent of modern genomics has provided new ways to link targets to diseases and validate these targets. The result is the potential for a new era of drug discovery transcriptomics or… Read More
Compound Management comes of age By Ian Yates The changing role of compound management in recent years has seen an often under-valued and under-resourced function being recognised as a key part of the drug discovery process. This article examines the challenges faced by compound management teams and, at a high… Read More
Balancing Quantity and Quality in Drug Discovery By Eva-Lotta Allan There is a need to innovate in order to stay ahead, a need to maximise the value of the R&D engine by increasing the flow of novel drug candidates and yet, reduce the time to market. Does access to more… Read More
Secondary Screening Workstations - The emergence of compact turnkey solutions that work By Dr John Comley With the launch of new workstations focused on secondary screening applications not only are we witnessing the shrinkage of laboratory automation but we are seeing the emergence of true walk-away solutions, ie set up… Read More
Protein Arrays for Assessment of Target Selectivity By Professor Ian Humphery-Smith, Dr Erik Wischerhoff and Dr Ryuji Hashimoto Transforming knowledge of the human genome into a lead optimisation tool. Genomics activity has been criticised for having elucidated a plethora of potentially interesting drug targets, each awaiting further validation, but having… Read More
Better drugs by MICROARRAY By Dr Mark Schena Microarray analysis allows the elucidation of biological processes and pathways on a genomic scale. This revolutionary technology promises an unprecedented view of drug action and side reaction, the ability to identify drug targets and optimise lead compounds, the capacity to predict patient… Read More
Predictive chemoinformatics applications to the pharmaceutical industry By Dr Leslie J. Browne and Laurie L.Taylor While significant advances in chemoinformatics present tremendous opportunities to improve human health, the future of chemoinformatics in the pharmaceutical industry is not without significant challenges. Chemoinformatics is the result of collective advances in chemistry, biology,… Read More
Proteomatics - New information resources for proteomics By Dr David J Parry-Smith and Dr David S Bailey Proteomics is the science of understanding protein architectures at a supramolecular level, whereas the realm of understanding the organisation of biological information in its totality belongs to bioinformatics. Somewhat more prosaically, industrial bioinformatics… Read More
The emergence of pharmacogenomics within the pharmaceutical industry By Aidan Power, Suzin Webb, Dr Albert Seymour and Dr Patrice Milos The sequencing of the human genome represents one of the most significant scientific advances of the 20th century that will shape the foundation of medical research well into the 21st. Read More
The importance of using human-based models in gene and drug discovery By Dr Michael G. Palfreyman, Dr Vinod Charles and Jeffrey Blander Completion of the human genome sequence has opened an unprecedented opportunity to discover the genetic contribution to many of the complex diseases that afflict humans and to use… Read More
By Dr Roger A. Edwards, Dr Kai Zhang and Louise Firth Different companies have employed various techniques and strategies for addressing productivity issues in the chemistry functions within pharmaceutical discovery and preclinical development. We benchmarked lead optimisation, clinical candidate selection, and chemistry support for preclinical development before IND filing in… Read More
Drug development for skin diseases based on functional genomics By Dr Jorn-Peter Halle With the high number of sufferers from skin disease around the world, it is astonishing that there are relatively few treatments available and that many of these only serve to relieve symptoms. Can drug development based on… Read More
Fine-tuning the technology strategies for lead finding By Sandra Fox, Dr Shauna Farr-Jones, Dr Lynne Sopchak and Dr Helen Wang HTS has become the workhorse of pharmaceutical and biotechnology companies' drug discovery efforts, with expanding responsibilities and increasing pressures to screen more targets with better compound libraries to find high-quality… Read More
Monoclonal Antibodies - Magic bullets or a shot in the dark By Dr Fiona Adair It has been 16 years since the first monoclonal antibody was approved for therapy in acute transplant rejection. Now, with a further nine therapeutic monoclonal antibodies approved for use and some 16 in phase III… Read More
Nanolitre Dispensing - On the point of delivery By Dr John Comley Precise low-volume liquid handling methodologies are still sought after by those interested in enabling miniaturised HTS. This article reviews the need for nanolitre dispensing and provides a current perspective on those emerging technologies that have the potential to… Read More
SNP Genotyping in Drug Development By Dr Nicholas C. Dracopoli and Dr Kim E. Zerba SNP-based candidate gene analyses are likely to have a significant impact on predicting drug efficacy and will, undoubtedly, impact on the pharmaceutical industry's development strategies as a whole over the next few years. The human… Read More